Why the study?
Positive calcium scores correlate with increased cardiovascular risk, but no therapies are known to reliably reverse calcium scores, and the mechanism of chelation therapy remains unknown.
Does intravenous calcium EDTA chelation reduce calcium scores in asymptomatic patients with a positive calcium score?
Does intravenous calcium EDTA chelation reduce calcium scores in asymptomatic patients with a positive calcium score?
Intravenous calcium EDTA chelation was associated with a reduction in calcium scores in a small cohort of asymptomatic patients, suggesting a potential novel approach for primary prevention that requires validation in larger randomized trials.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for IV EDTA chelation in asymptomatic coronary calcium; randomized trials needed before any practice change.
This pilot study presents a retrospective analysis of 10 asymptomatic patients with a positive calcium score who received a series of intravenous calcium ethylenediaminetetraacetic acid (EDTA) chelations. Current standards for cardiovascular risk stratification include assessments of cholesterol, blood pressure, blood sugar, lifestyle, obesity, and family history. Despite addressing traditional risk factors, myocardial infarctions and cerebrovascular accidents remain the leading causes of death and disability worldwide. Asymptomatic decay of the vascular system is a prelude to catastrophic events, and calcium scores are emerging as a significant adjunct for risk assessment. Positive calcium scores correlate with an increased risk of cardiovascular events. However, there are no therapies known to reliably reverse calcium scores. Previous studies have demonstrated that intravenous chelation therapy reduces cardiovascular morbidity and mortality in patients with a prior history of myocardial infarction; however, its mechanism of action is unknown. One theory is that chelation therapy would reverse calcium buildup in coronary arteries, which is known to have a positive correlation with the risk of having a cardiovascular event. The 10 patients had no prior history of coronary artery disease. Infusions were administered in an outpatient setting. Patients were encouraged to receive a treatment every month. No other supplements or prescriptions were required as part of the treatment. An average of 26.9 chelations were administered over an average of 37.9 months. Calcium scores decreased by an average of 27.38%, and all 10 patients experienced a reduction in scores. This study demonstrates that chelation has the potential to reduce calcium scores. Since calcium scores correlate with cardiovascular risk, reducing the calcium score may reduce the risk of an event. If these results are supported by larger, placebo-controlled studies, chelation therapy may become an option that could be added to statins and other FDA-approved therapies for primary prevention in patients with a positive calcium score.
No takes yet. Share an insight, caveat, or question.
Petteruti et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: